Theratechnologies (NASDAQ:THTX) Posts Earnings Results, Misses Expectations By $0.14 EPS

Posted by Linda Flegge on Feb 26th, 2025

Theratechnologies (NASDAQ:THTX – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.14), Zacks reports.

Theratechnologies Stock Performance

Shares of THTX traded down $0.13 during mid-day trading on Wednesday, hitting $1.69. The company’s stock had a trading volume of 221,041 shares, compared to its average volume of 110,541. The stock’s 50-day moving average is $1.75 and its two-hundred day moving average is $1.45. The firm has a market capitalization of $77.48 million, a PE ratio of -17.14 and a beta of 1.26. Theratechnologies has a one year low of $1.08 and a one year high of $2.18.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Theratechnologies stock. Bank of America Corp DE grew its stake in shares of Theratechnologies Inc. (NASDAQ:THTX – Free Report) by 1,416.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,487 shares of the company’s stock after buying an additional 15,400 shares during the period. Bank of America Corp DE’s holdings in Theratechnologies were worth $30,000 as of its most recent filing with the Securities and Exchange Commission.

Analysts Set New Price Targets

Separately, Research Capitl raised shares of Theratechnologies to a “strong-buy” rating in a report on Friday, February 14th.

View Our Latest Analysis on Theratechnologies

About Theratechnologies

(Get Free Report)

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.